Atorvastatin in Pulmonary Hypertension

Inclusion Criteria: * Able to understand and willing to sign the informed consent form * \<=65 and \>=18years old * Diagnosis of pulmonary arterial hypertension (Mean pulmonary artery pressure greater than 25 mm Hg at rest with a pulmonary capillary wedge pressure less than 15 mm Hg )that is a) idiopathic, b) familial, or c) associated with connective-tissue disease, d)congenital systemic-to-pulmonary shunt occurring after surgical/interventional repair that had been performed at least five years previously or in the absence of indications for surgery/intervention treatment e) chronic thromboembolism PAH in the absence of indications for surgery * Patients in WHO functional class II to III * Vasodilator Testing nonresponders * Baseline six-minute walking distance between 100 and 460 m Exclusion Criteria: * PAH related to other etiologies (Groups 2, 3 and 5 pulmonary hypertension) * A forced expiratory volume in one second/ forced vital capacity bellow 50% or a total lung capacity of less than 60 percent predicted value * A 6-minute walk distance of less than 100 or more than 460 m * A positive acute vasodilator response * Current treatment with calcium-channel blockers or specific therapy (endothelin receptor antagonist, phosphodiesterase-5 inhibitor, or prostacyclin) * Inability to perform 6-minute walk test * Serum transaminase level three times above the upper limit of normal * Creatine kinase level five times above the upper limit of normal * Previously diagnosed heart disease such as serious cardiac arrhythmias, unstable angina pectoris, myocardial infarction * History of transient ischemia attack or stroke within three months * Bleeding disorder * Positive pregnancy test or breastfeeding practice * History or suspicion of inability to cooperate